Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story behind CER-T cell breakthroughs often means digging through pages of biotech jargon in CERo Therapeutics’ SEC disclosures. If you have ever wondered why the company’s cash runway shifts quarter to quarter—or need to confirm options exercised by executives—those answers are deep inside the filings and easy to miss.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR, then delivers concise explanations in plain English. Whether it’s a CERo Therapeutics quarterly earnings report 10-Q filing that breaks down R&D spend, or an unexpected 8-K detailing a trial milestone, we surface what matters and link straight to the source. You will even receive CERo Therapeutics Form 4 insider transactions real-time, so you can monitor executive stock moves before markets react.
Here is what you can explore right now:
- CERo Therapeutics annual report 10-K simplified—cash position, pipeline progress, risk factors.
- CERo Therapeutics insider trading Form 4 transactions and executive stock transactions Form 4, complete with trend charts.
- CERo Therapeutics proxy statement executive compensation, summarized to highlight incentive alignment.
- CERo Therapeutics 8-K material events explained—partnerships, clinical data releases, or financings.
Still comparing notes? Use our AI-generated “Key Points” to move from document to decision in minutes. From understanding CERo Therapeutics SEC documents with AI to a deeper CERo Therapeutics earnings report filing analysis, every disclosure is now at your fingertips—updated in real time and explained simply.
CERo Therapeutics Holdings, Inc. reported interim results showing limited cash runway, ongoing operating losses and material financing activity. The company had approximately $3.23 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $81.4 million. For the six months ended June 30, 2025 the Company recorded a net loss of $5.42 million, and a year-to-date net loss of $10.52 million for 2024 comparisons presented. During the period the Company raised proceeds of approximately $4.2 million from a February 2025 securities offering, $2.9 million from warrant exercises, subscriptions and ELOC fundings, and $2.2 million from sales of Series D preferred stock. The filing discloses substantial doubt about the Company’s ability to continue as a going concern without additional financing. The Company effected reverse stock splits and recorded significant preferred-to-common conversions and related deemed dividends and stock-based inducement expenses that materially affected reported equity and net loss.
Cero Therapeutics Holdings received a Schedule 13G filing disclosing that Armistice Capital, LLC and Steven Boyd together beneficially own 63,308 shares of the company’s common stock, representing 4.99% of the class. Armistice Capital is the investment manager of a Master Fund that directly holds the shares and, under its Investment Management Agreement, Armistice exercises shared voting and dispositive power over those shares. Mr. Boyd, as managing member of Armistice, is reported to share those voting and disposition powers. The filing states the position is held in the ordinary course of business and not to influence control.
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
